Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02925949 · ClinicalTrials.gov registry record · NA
Duo Partnership Adherence Commitment Therapy
A NA study of HIV/AIDS, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 288
- Enrollment target
- 1
- Study location
NCT02925949: Completed NA study of HIV/AIDS, sponsored by University of California, San Francisco.
NCT02925949 is a NA study of HIV/AIDS that has completed, run by University of California, San Francisco. The registered enrollment target is 288 participants, below the 33,176-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02925949, a NA study of HIV/AIDS, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 288 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized controlled trial of a new behavioral intervention designed to improve engagement in HIV care for couples. Investigators will compare the HIV viral load outcomes of couples randomized to a couples-based adherence intervention (DuoPACT) or to an individual adherence intervention (LifeSteps).
Primary Outcome
Follow-up blood draws will be performed on all HIV+ partners at 3, 6, and 9 months post randomization. HIV-1 viral load levels will be measured by the COBAS® AmpliPrep/COBAS® TaqMan® HIV test kit (Roche Molecular Systems, Inc.), which has a threshold for undetectability = \< 20 copies/mL.
Conditions Studied
Interventions
- BEHAVIORAL DuoPACT
- BEHAVIORAL LifeSteps
Study Locations (1)
California
- Center for AIDS Prevention Studies - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2022-06-01 |
| Phase | NA |
What the finished NCT02925949 record still lists
NCT02925949 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, below the 33,176-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower).
The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 2 interventions - of which DuoPACT is the first listed.
NCT02925949 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02925949 about?
NCT02925949 is a clinical study titled "Duo Partnership Adherence Commitment Therapy". This is a randomized controlled trial of a new behavioral intervention designed to improve engagement in HIV care for couples. Investigators will compare the HIV viral load outcomes of couples randomized to a couples-based adherence intervention (DuoPACT) or to an individual adherence intervention (...
What is the current status of trial NCT02925949?
This trial is currently completed. It is a NA study. The enrollment target is 288 participants. The study started on 2017-08-14. Estimated completion is 2022-06-01.
What conditions does trial NCT02925949 study?
This clinical trial studies the following conditions: HIV/AIDS.
What interventions are being tested in trial NCT02925949?
The interventions under investigation include: DuoPACT (BEHAVIORAL), LifeSteps (BEHAVIORAL).
Who is sponsoring clinical trial NCT02925949?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02925949 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV/AIDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02925949's enrollment target sits among peer trials
288 21st of 61 higher than 41 of 61 other HIV/AIDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV/AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence
RECRUITING · NA
-
MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM
RECRUITING · NA
-
MyPEEPS LITE Trial
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Improving the Organizational Social Context to Address Structural Racism and Discrimination
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI